What drugs target HCV NS5B polymerase and NS5A protein?

8+ drugs target HCV NS5B polymerase and NS5A protein, including sofosbubir/velpatasvir, sofosbuvir/velpatasvir crushed, Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir and Velpatasvir, sofosbuvir/ledipasvir.

What drug classes act on HCV NS5B polymerase and NS5A protein?

Drug classes acting on HCV NS5B polymerase and NS5A protein include Direct-acting antiviral (DAA) combination.

HCV NS5B polymerase and NS5A protein — Drug Target

8 drugs 7 marketed 1 in Phase 3

All drugs that target HCV NS5B polymerase and NS5A protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Direct-acting antiviral (DAA) combination

Marketed (7)

sofosbubir/velpatasvir · Partners in Health · Direct-acting antiviral (DAA) combination · Virology/Hepatology
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.
sofosbuvir/velpatasvir crushed · Radboud University Medical Center · Direct-acting antiviral (DAA) combination · Infectious Disease / Virology
Sofosbuvir/velpatasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication.
Sofosbuvir/Ledipasvir x 12 weeks · Medical University of South Carolina · Direct-acting antiviral (DAA) combination · Virology/Hepatology
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while ledipasvir inhibits NS5A protein, together blocking viral replication.
Sofosbuvir and Velpatasvir · Hannover Medical School · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Sofosbuvir and velpatasvir are direct-acting antivirals that inhibit hepatitis C virus NS5B polymerase and NS5A protein, blocking viral replication.
sofosbuvir/ledipasvir · University of Texas Southwestern Medical Center · Direct-acting antiviral (DAA) combination · Infectious Disease / Virology
Sofosbuvir/ledipasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication.
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] · Ohio State University · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Sofosbuvir and velpatasvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5B polymerase and NS5A protein, respectively.
Sofosbuvir / Velpatasvir · Peking University First Hospital · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.

Phase 3 pipeline (1)

Combined Therapy SOF and DCV · Yassin Abdelghaffar Charity Center for Liver Disease and Research · Direct-acting antiviral (DAA) combination · Virology / Hepatology
This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes.